Table 4.

Risk of detection of advanced colorectal neoplasia by genotype and folate treatment

VariantGenotypeIntervention
Pinteraction
Folate-treated
Non-folate-treated
Advanced colorectal neoplasia* detected/not detectedRR (95% CI)Advanced colorectal neoplasia* detected/not detectedRR (95% CI)
MTHFR C677TCC20/108Reference14/102Reference0.95
CT15/1041.04 (0.56-1.92)15/1101.02 (0.53-1.95)
TT3/290.89 (0.28-2.81)3/231.16 (0.35-3.88)
CT/TT18/1331.01 (0.56-1.83)18/1331.04 (0.56-1.94)
MTHFR A1298CAA19/118Reference16/115Reference0.89
AC12/1010.81 (0.42-1.54)12/1020.86 (0.42-1.76)
CC7/221.21 (0.56-2.59)4/181.80 (0.72-4.49)
AC/CC19/1230.92 (0.52-1.61)16/1200.99 (0.52-1.90)
MTR A2756GAA28/163Reference20/170Reference0.57
AG10/680.90 (0.49-1.66)12/581.53 (0.81-2.89)
GG0/100/7
AG/GG10/780.80 (0.43-1.50)12/651.35 (0.70-2.59)
MTRR A66GAA13/51Reference10/43Reference0.32
AG17/1220.49 (0.25-0.96)9/1180.45 (0.20-1.03)
GG8/680.39 (0.19-0.82)§13/740.84 (0.41-1.73)
AG/GG25/1900.45 (0.24-0.84)§22/1920.62 (0.32-1.22)
TSER3R/3R14/69Reference7/60Reference0.42
3R/2R15/1170.66 (0.35-1.25)18/1181.19 (0.55-2.61)
2R/2R9/510.98 (0.46-2.18)7/560.93 (0.36-2.35)
3R/2R and 2R/2R24/1680.76 (0.42-1.36)25/1741.10 (0.53-2.32)
TS high/lowHigh17/95Reference12/84Reference0.96
Low21/1420.98 (0.56-1.79)20/1500.89 (0.47-1.69)
TS 1494del6wt/wt22/115Reference14/121Reference0.35
wt/−6bp14/1060.74 (0.40-1.38)14/1041.20 (0.64-2.27)
−6bp/−6bp2/200.57 (0.18-1.82)4/102.30 (0.95-5.57)
wt/−6bp and −6bp/−6bp16/1260.72 (0.40-1.29)18/1141.35 (0.74-2.45)
  • * Advanced colorectal neoplasia was defined as CRAs with villous or tubulovillous features, size ≥1 cm, severe dysplasia, or CRC.

  • RR and 95% CI adjusted for sex and interval between entry and follow-up colonoscopy.

  • P < 0.05.

  • § P = 0.01.

  • High and low TS expression genotypes based on TSER and TSER 3R G>C polymorphisms (high: 3RG/3RG, 3RG/3RC, 3RG/2R; low: 3RC/3RC, 3RC/2R, 2R/2R).